Aston University's Professor Nicola Logan and the University of Huddersfield’s Niall Hynes on evolving research, looking to ...

The glasses, by Essilor Stellest, are approved by the FDA to slow nearsightedness in 6- to 12-year-olds.

(MENAFN- GetNews) Taken together this most recent low dose atropine study and regulatory interaction demonstrate the endpoints needed for approval by region and the type of clinical importance ...

DPTX3186 targets the Wnt/β-catenin pathway, crucial in gastric cancer, by forming drug-induced condensates to modulate β-catenin activity. Fast track designation accelerates development and review, ...

With two of the country’s premier government hospitals in Delhi—Safdarjung Hospital and the All India Institute of Medical Sciences (AIIMS)—setting up dedicated clinics to treat myopia, experts say ...

Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer ...

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...

NEW YORK, November 12, 2025--(BUSINESS WIRE)--Oar Health, a virtual care platform offering access to medication for alcohol use disorder, today announced the launch of Clutch™, the first orally ...

Headquartered in Fort Worth, Texas, Bell Textron is a wholly-owned subsidiary of Textron Inc. It operates in the military and the commercial aerospace sectors. It should be noted that, a year ago, the ...

Laughing matters. It always has. But laughing may matter even more in modern times. Does anyone think that during the Middle Ages, or even in the late 19th century, ordinary citizens spent as much ...

PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Axalta (NYSE: AXTA), a leading global coatings company, has won a 2025 R&D 100 Award in the Mechanical/Materials category for its Spies Hecker ...

Anti-VEGF therapy for patients with retinopathy of prematurity reduces myopia compared with laser treatments, but comes with other risks.